711 ORAL Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients

2005 ◽  
Vol 3 (2) ◽  
pp. 201-202 ◽  
Keyword(s):  
Survival Analysis ◽  
Randomized Trial ◽  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function

2002 ◽  
Vol 13 (8) ◽  
pp. 847-849 ◽  
Author(s):  
Sebastian Bauer ◽  
Volker Hagen ◽  
Hermann J Pielken ◽  
Peter Bojko ◽  
Siegfried Seeber ◽  
...  
Keyword(s):  
Liver Function ◽  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Impaired Liver Function ◽  
Stromal Tumors ◽  
Impaired Liver

A Review of Resistance Patterns and Phenotypic Changes in Gastrointestinal Stromal Tumors Following Imatinib Mesylate Therapy

2007 ◽  
Vol 11 (6) ◽  
pp. 758-766 ◽  
Author(s):  
Kai Bickenbach ◽  
Rebecca Wilcox ◽  
Jula Veerapong ◽  
Hedy Lee Kindler ◽  
Mitchell C. Posner ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors ◽  
Phenotypic Changes ◽  
Resistance Patterns

scholarly journals Approval Summary: Imatinib Mesylate in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors

2010 ◽  
Vol 15 (3) ◽  
pp. 300-307 ◽  
Author(s):  
Martin H. Cohen ◽  
Patricia Cortazar ◽  
Robert Justice ◽  
Richard Pazdur
Keyword(s):  
Imatinib Mesylate ◽  
Adjuvant Treatment ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

scholarly journals The Inside Mystery of Jejunal Gastrointestinal Stromal Tumor: A Rare Case Report and Review of the Literature

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
A. K. Dhull ◽  
V. Kaushal ◽  
R. Dhankhar ◽  
R. Atri ◽  
H. Singh ◽  
...  
Keyword(s):  
High Risk ◽  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Rare Case ◽  
Immunohistochemical Analysis ◽  
Resected Specimen ◽  
Stromal Tumors ◽  
Primary Gist ◽  
Large Size ◽  
Operative Findings

Gastrointestinal stromal tumors (GISTs) are malignant and rare form of soft tissue sarcoma of the digestive tract. The incidence of gastrointestinal stromal tumors is very low Kramer et al. 2005 Jejunal GISTs are extremely rare. Here we present a rare case of jejunal GIST with unusually large size at presentation. The patient presented with severe abdomen pain, exophytic growth, and dimorphic anemia. Surgical resection of the tumor was carried out, and operative findings revealed a 15 × 10 cm growth, arising from serosal surface of jejunum, at the antimesenteric surface. Diagnosis in this case was made by subjecting the resected specimen to immunohistochemical analysis. In view of large size of the resected tumor, and high-risk histopathological features, imatinib mesylate 400 mg once daily was given as adjuvant chemotherapy. Patient is asymptomatic without any evidence of tumor recurrence after six months of postoperative followup. Imatinib as such is recommended in metastatic, residual or recurrent cases of GISTs or which are surgically not removable; however, recent recommendations suggests the use of imatinib mesylate after radical surgery in high-risk cases, because it has shown a significant decrease in the recurrence rate, and the Food and Drug Administration (FDA) has also approved the use of imatinib as adjuvant therapy after complete resection of localized, primary GIST.

scholarly journals Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute

2006 ◽  
Vol 22 (12) ◽  
pp. 599-603
Author(s):  
Hui-Hua Hsiao ◽  
Yi-Chang Liu ◽  
Hui-Jen Tsai ◽  
Li-Tzong Chen ◽  
Ching-Ping Lee ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors
Sign in / Sign up

Export Citation Format

Share Document